Evaluation of the host response to endotoxemia of FVIII and FIX deficient mice

Haemophilia

Volumn 17, Issue 5, 2011, Pages 800-807

  Vancine, S M C ^a   Picoli Quaino, S K ^a   Costa, D S P ^a   Montalvao, S A L ^a   Ozelo, M C ^a   Annichino Bizzacchi, J M ^a   De Paula, E V ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Disseminated intravascular coagulation; Endotoxemia; Factor IX; Factor VIII; Haemophilia; Sepsis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYTOKINE; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; ENDOTOXEMIA; EVALUATION; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HISTOLOGY; IMMUNE RESPONSE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SURVIVAL; TISSUE INJURY;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD COAGULATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; ESCHERICHIA COLI INFECTIONS; FIBRINOGEN; HEMOPHILIA A; HEMOPHILIA B; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; SURVIVAL ANALYSIS;

EID: 80052038300     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02598.x     Document Type: Article

References (26)

1. Abraham E, Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 2007; 35: 2408-16.
2. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001; 29: S90-4.
3. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S9-14.
4. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49: 5-7.
5. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-47.
6. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-78.
7. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
8. Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007; 282: 33022-33.
9. Schoenmakers SH, Versteeg HH, Groot AP, Reitsma PH, Spek CA. Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. J Thromb Haemost 2004; 2: 2185-93.
10. Xu H, Ploplis VA, Castellino FJ. A coagulation factor VII deficiency protects against acute inflammatory responses in mice. J Pathol 2006; 210: 488-96.
11. Tucker EI, Gailani D, Hurst S, Cheng Q, Hanson SR, Gruber A. Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. J Infect Dis 2008; 198: 271-4.
12. Schoenmakers SH, Bruggemann LW, Groot AP, Maijs S, Reitsma PH, Spek CA. Role of coagulation FVIII in septic peritonitis assessed in hemophilic mice. J Thromb Haemost 2005; 3: 2738-44.
13. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
14. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
15. Hubbard WJ, Choudhry M, Schwacha MG et al. Cecal ligation and puncture. Shock (Augusta, Ga) 2005; 24 (Suppl. 1): 52-7.
16. Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P. Experimental models of sepsis and their clinical relevance. Shock (Augusta, Ga) 2008; 30 (Suppl. 1): 53-9.
17. Kung SH, Hagstrom JN, Cass D et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998; 91: 784-90.
18. Abraham E. Do coagulation abnormalities contribute to sepsis associated organ failure? Crit Care Med 2006; 34: 1842-4.
19. Cao C, Gao Y, Li Y, Antalis TM, Castellino FJ, Zhang L. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin investig 2010; 120: 1971-80.
20. Xu J, Zhang X, Pelayo R et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15: 1318-21.
21. Camerer E, Cornelissen I, Kataoka H, Duong DN, Zheng YW, Coughlin SR. Roles of protease-activated receptors in a mouse model of endotoxemia. Blood 2006; 107: 3912-21.
22. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood 2006; 108: 3053-60.
23. Konkle BA, Kessler C, Aledort L et al. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 2009; 15: 1197-209.
24. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
25. Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. Semin Thromb Hemost 2010; 36: 367-77.
26. Opal SM. Clinical trial design and outcomes in patients with severe sepsis. Shock 2003; 20: 295-302.